News
Public · Published
Herbalife Shifts to Broader Health Focus Amid Weight-Loss-Drug Surge — Interview
Herbalife is broadening its focus from weight loss to wider nutritional health as GLP-1 weight-loss drugs surge. Interim CEO John DeSimone said the company is emphasizing protein products, in-person nutrition clubs and sports lines; protein-based products account for 30% of sales. Third-quarter sales rose 6% to $1.35 billion, above analysts' $1.31 billion expectation.
Published:
Updated:
What happened
Herbalife is broadening its focus from weight loss to wider nutritional health as GLP-1 weight-loss drugs surge. Interim CEO John DeSimone said the company is emphasizing protein products, in-person nutrition clubs and sports lines; protein-based products account for 30% of sales. Third-quarter sales rose 6% to $1.35 billion, above analysts’ $1.31 billion expectation.
Confirmed
Global impact / market context
The strategy aims to keep Herbalife’s products relevant as weight-loss drugs reshape consumer choices, by highlighting uses beyond weight loss. Protein already makes up 30% of sales, so sustained demand for these products could support revenue; nutrition clubs and sports lines offer additional routes to attract customers.
Analyst inference
The article presents a mixed backdrop: GLP-1 drugs are driving a surge that challenges Herbalife’s weight-loss positioning, while protein demand and third-quarter sales provide support. Sales exceeded the cited analyst expectation, but the article gives no outlook or evidence that this growth will continue.
Analyst inference
What to watch
- Watch whether Herbalife continues to report growth in protein products, which account for 30% of sales, and whether broader nutrition messaging helps sustain that demand. Analyst inference
- Track sales at in-person nutrition clubs and the contribution of sports lines, which management identified as growth drivers but did not quantify in the article. Analyst inference
- Look for further detail from management on how GLP-1 drug use is changing customer demand and whether the shift in product positioning supports revenue. Analyst inference
Evidence
- Original source link unavailable